MethodsTwenty-seven participants with COPD, 27 with bronchiectasis and 17 control subjects completed reflux symptom evaluation and dual-channel 24h oesophageal pH monitoring. In those with lung disease, pepsin levels in sputum samples were measured using enzyme-linked immunosorbent assay, with disease severity (lung function and high-resolution computed tomography) also measured. ResultsThe prevalence of GOR in COPD was 37%, in bronchiectasis was 40% and in control subjects was 18% (P=0.005).
Of those diagnosed with GOR, clinically silent reflux was detected in 20% of participants with COPD and 42% with bronchiectasis. While pepsin was found in 33% of COPD and 26% of bronchiectasis participants, the presence of pepsin in sputum was not related to a diagnosis of GOR based on oesophageal pH monitoring in either condition. Neither a diagnosis of GOR nor the presence of pepsin was associated with increased severity of lung disease in COPD or bronchiectasis. ConclusionsThe Linsitinib concentration prevalence of GOR in COPD or bronchiectasis is twice that of the control population, and the diagnosis could not be based on symptoms alone. Pepsin was detected in sputum in COPD and bronchiectasis, Selleck Galunisertib suggesting a possible role of pulmonary aspiration, which requires further exploration. The prevalence of gastro-oesophageal reflux in adults with chronic obstructive pulmonary disease or bronchiectasis
is twice as high compared with individuals without lung disease. The findings of this observational study suggest that gastro-oesophageal reflux is a common comorbidity across the disease spectrum in adults with these lung conditions.”
“ObjectivesTobramycin inhalation solution (TIS; TOBI (R)) has improved forced expiratory volume in 1sec (FEV1) in cystic fibrosis (CF) trials. Using data from the Epidemiologic Study of CF (ESCF), we assessed BVD-523 concentration the change in level and trend of FEV1 % predicted (pred) over a 2-year period associated with initiation of TIS during routine clinical practice. MethodsPatients age 8-38 years and in ESCF for 2 years before treatment with TIS as a chronic therapy were selected if they remained on therapy for 2 years,
defined as being on TIS for at least 3 months per year (C-TIS group). Comparator intervals age 8-38 years used TIS smaller than 10% of the time. For each interval, we estimated the level and trend (rate of decline) in FEV1 % pred before and after the index using a piecewise linear mixed-effects model adjusted for potential confounders. ResultsDuring the 2-year pre-index period the C-TIS group (n=2,534) had a more rapid decline in FEV1 (-2.49% vs. -1.39% pred/year) and a lower FEV1 at index (62.6% vs. 74.7% pred) than the comparator group (N=17,656 intervals). After starting chronic TIS, the FEV1 trend line over the 2-year post-index period was higher, but the comparator group’s FEV1 was essentially unchanged (difference 2.22, P smaller than 0.001). Change in slope was not different between groups (0.06, P=0.82).